Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures

Published
04 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$4.27
1.3% undervalued intrinsic discount
15 Aug
US$4.21
Loading
1Y
-40.3%
7D
0.5%

Author's Valuation

US$4.3

1.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25
Fair value Increased 8.47%

Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.

Shared on01 May 25
Fair value Increased 19%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 16%

AnalystConsensusTarget has decreased revenue growth from 7.2% to 4.5% and increased shares outstanding growth rate from 0.0% to 0.0%.